⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24211928 | 1.00 | — | — | |
| SCHEMBL7520886 | 0.81 | — | — | |
| SCHEMBL7518983 | 0.81 | — | — | |
| SCHEMBL7521176 | 0.81 | — | — | |
| SCHEMBL7518978 | 0.81 | — | — | |
| SCHEMBL7520492 | 0.81 | — | — | |
| SCHEMBL16401948 | 0.79 | CYP2C19 (0.44) | — | |
| SCHEMBL7516847 | 0.79 | — | — | |
| SCHEMBL7522694 | 0.79 | — | — | |
| SCHEMBL7521384 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948177-A1 | METHODS FOR OPTIMIZING DOMAIN STABILITY OF BINDING PROTEINS | AbbVie Inc. (US) | 2015-12-02 | — | — | EP | claimed |
| WO-2014116596-A1 | METHODS FOR OPTIMIZING DOMAIN STABILITY OF BINDING PROTEINS | ABBVIE, INC. (US) | 2014-07-31 | — | — | WO | claimed |
| WO-2023136279-A1 | CRYSTAL OF SUBSTITUTED PIPERIDINE COMPOUND, SALTS OF SUBSTITUTED PIPERIDINE COMPOUND, AND CRYSTALS THEREOF | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2023-07-20 | — | — | WO | disclosed |
| CN-115884971-A | Substituted piperidine compounds and uses thereof | 卫材R&D管理有限公司 | 2023-03-31 | — | — | CN | disclosed |
| WO-2022014680-A1 | SUBSTITUTED PIPERIDINE COMPOUND AND APPLICATION THEREOF | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 2022-01-20 | — | — | WO | disclosed |
| CN-109776537-A | Purinedione as WNT pathway modulators | 新加坡科技研究局 | 2019-05-21 | — | — | CN | disclosed |
| EP-3313825-A1 | GLUCOSE UPTAKE INHIBITORS | Kadmon Corporation, LLC (US) | 2018-05-02 | — | — | EP | disclosed |
| WO-2016210330-A1 | GLUCOSE UPTAKE INHIBITORS | KADMON CORPORATION, LLC (US) | 2016-12-29 | — | — | WO | disclosed |
| US-20160113930-A1 | COMPOUNDS FOR USE IN TREATING RETT SYNDROME | VITAE PHARMACEUTICALS, INC. | 2016-04-28 | — | — | US | disclosed |
| US-20160113930-A1 | COMPOUNDS FOR USE IN TREATING RETT SYNDROME | VITAE PHARMACEUTICALS, INC. | 2016-04-28 | — | — | US | disclosed |
| CN-103130652-A | Method preparing aromatic primary amine compound from phenol type compound | UNIV ZHEJIANG | 2013-06-05 | — | — | CN | disclosed |
| US-7868032-B2 | Prostamide receptor antagonists | ALLERGAN, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| WO-2009143485-A1 | DIAZONAMIDE ANALOGS | JOYANT PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20080096240-A1 | NOVEL PROSTAMIDE RECEPTOR ANTAGONISTS | WOODWARD DAVID F | 2008-04-24 | — | — | US | disclosed |
| EP-1660439-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005014533-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |